Commentary: Companion Diagnostics and Complementary Diagnostics in Clinical Practice: Better Medicine or Competitive Disadvantage?
We are pleased to present the second installment in our recurring column, Pharma Insights. This month we take a look at an interesting twist in how the use of complementary and companion diagnostics is playing out in real-world clinical practice. In a health care system that increasingly seeks to more precisely target therapeutic approaches to diseases, diagnostic testing is the key to unlocking greater value in pharmacotherapy. Two classes of diagnostic tests—companion and complementary diagnostics—have emerged to address this need.
Commentary: The Importance of Immunogenicity of Biosimilars (Video)
The FDA recently approved the biosimilar infliximab and found that from an immunogenicity profile it was more or less similar, which is important for payers and providers, explained Jeremy Schafer, PharmD, MBA, vice president and director of specialty solutions at Precision For Value.
Commentary: When Medication Price Deflates Perception of Therapeutic Effect
Rick Lifsitz and Larry Blandford discuss if higher prices really translate into greater perceived therapeutic effectiveness in a new commentary for Journal of Clinical Pathways
LehmanMillet Becomes precisioneffect Following Acquisition – Medical Marketing & Media
Carolyn Morgan discusses the rebrand of LehmanMillet to precisioneffect in Medical Marketing & Media.
LehmanMillet Is Now precisioneffect
37-Year-Young Advertising Agency Gets a New Name, New Locations and
Expanded Service Offering
Boston, March 29, 2016 – LehmanMillet, the only healthcare communications agency dedicated to working with companies seeking to change the standard of care, has changed its name to precisioneffect (www.precisioneffect.com). The impetus for the name change was the firm’s acquisition by Precision Medicine Group (PMG) in May of 2015. PMG is a specialized services company supporting next-generation approaches to drug development and commercialization.